How to Buy Keros Therapeutics Stock
Keros Therapeutics Inc
Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.
Keros Therapeutics stock last closed at $13.49, down 1.04% from the previous day, and has decreased 69.5% in one year. It has overperformed other stocks in the Biotechnology industry by 0.02 percentage points. Keros Therapeutics stock is currently +47.92% from its 52-week low of $9.12, and -81.36% from its 52-week high of $72.37.
There are currently 40.62M shares of KROS outstanding. The market value of KROS is $547.90M. In the last 24 hours, 1.57M KROS shares were traded.
How to Buy Keros Therapeutics Stock
Wondering how to invest in Keros Therapeutics stock? Here's how.
- Figure out where to buy Keros Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy Keros Therapeutics stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Choose your method of payment and add your info.
- Research Keros Therapeutics stock: The Keros Therapeutics ticker symbol is KROS. Is Keros Therapeutics stock a good investment? Should you buy shares of KROS? How do KROS's underlying business fundamentals look? Do top analysts think Keros Therapeutics is a good buy? Why has KROS's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if KROS is a good stock to buy).
- Place your KROS purchase: Decide if you will purchase KROS shares at the current market price or use a limit order to purchase KROS shares at a specific price.
- Monitor your investment in KROS: Create a watchlist to the latest updates on your position in Keros Therapeutics shares.
Step 1: Figure out where to buy Keros Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy KROS shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world markets: From Technology to Industrials, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you are able to invest in KROS stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start your new brokerage account.
- Submit your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've filled out your info on the best stock market app, your next step is to transfer the money for your investment:
Check out the tutorial below to see the process of transferring funds into your brokerage account.
Step 4: Research Keros Therapeutics stock
Once you have identified the best place to buy Keros Therapeutics stock, it's very important to analyze their stock before you invest, so you truly comprehend the risk and opportunity.
Keros Therapeutics shares at a glance
Fundamentals of KROS
WallStreetZen was designed to help part-time investors perform better fundamental analysis in less time.
You can see all of the due diligence checks on KROS's stock page.
Is KROS stock overvalued?
Investors use many financial metrics, analyses, models, and charts to gauge KROS's true value.
Using relative valuations metrics:
- KROS may be undervalued based on its P/B ratio of 0.75x, relative to Biotechnology industry P/B ratio of 4.43x
You can do more valuation analysis on KROS's stock here.
KROS Financials at a glance
Signs that KROS is financially healthy:
- There are more short-term assets than short-term liabilities on the KROS balance sheet.
- KROS has a low debt to equity ratio of 0.08.
- There are more short-term assets than long-term liabilities on the KROS balance sheet.
- KROS earnings of $14.56M is not sufficient to cover its interest payments.
- KROS profit margin has gone up from -68,505.1% to 2% in the past year.
- KROS's operating cash flow of $44.86M allows it to safely service it's debt of $18.41M.
- Total KROS debt is lower than 5 years ago, relative to shareholder equity.
Do analysts think it's a good time to buy KROS stock
Out of 8 sell side analysts who give forecasts on KROS, the consensus analyst rating on Keros Therapeutics is a Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent KROS Analyst Upgrades/Downgrades
Tiago Fauth, a bottom 5% analyst from Wells Fargo maintains KROS with a strong buy rating and lowers their KROS price target from $28.00 to $26.00, on Feb 27, 2025.
Joseph Catanzaro, a bottom 3% analyst from Piper Sandler maintains KROS with a strong buy rating and lowers their KROS price target from $40.00 to $15.00, on Jan 17, 2025.
Andreas Argyrides, a top 6% analyst from Wedbush downgrades KROS to a hold rating and lowers their KROS price target from $47.00 to $15.00, on Jan 17, 2025.
You can dig deeper into what analysts are projecting on the Keros Therapeutics stock forecast page.
KROS Momentum
KROS Performance Metrics
Last year, KROS revenue was $214.71M. Over the last 5 year, KROS's revenue has grown by 95.6% per year. This was faster than the Biotechnology industry average of 42.28%.
Find out more about KROS's earnings and revenue performance here.
Are KROS executives and large shareholders buying or selling the stock?
In the last 12 months, insiders at KROS have bought more shares than they have sold.
Adar1 Capital Management LLC, 10% Owner of KROS, was the latest KROS insider to sell. They sold $6,000.00 worth of KROS stock on Jun 20, 2025.
Get more info about who owns KROS shares here.
Does KROS provide a stable income stream?
No, Keros Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your KROS purchase
You have two primary options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually fine. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a given price, use a limit order.
Hit the Open button and eToro will place your order.
If you need additional info about investing in stocks on eToro, click the how to video below:
Step 6: Monitor your investment in KROS
Now that you own some KROS shares, you'll want to keep up with your new investment.
Create a watchlist to get notified of important updates regarding your KROS stock.
KROS Feed
How to Buy Stock in Keros Therapeutics
To reiterate, here are the 6 steps for buying Keros Therapeutics stock:
- Figure out where to buy Keros Therapeutics stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Keros Therapeutics stock
- Place your KROS purchase
- Monitor your investment in KROS
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Keros Therapeutics, create a watchlist on WallStreetZen today.
Other Articles You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.